Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.

Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ.

Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9.

2.

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Schreiber V, Illuzzi G, Héberlé E, Dantzer F.

Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Review. French.

PMID:
26384693
3.

Advances in PARP inhibitors for the treatment of breast cancer.

Dizdar O, Arslan C, Altundag K.

Expert Opin Pharmacother. 2015;16(18):2751-8. doi: 10.1517/14656566.2015.1100168. Epub 2015 Oct 20. Review.

PMID:
26485111
4.

Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?

Plummer R.

Breast Cancer Res. 2011 Aug 16;13(4):218. doi: 10.1186/bcr2877. Review.

5.

[Cancer therapy by PARP inhibitors].

Seimiya H.

Nihon Rinsho. 2015 Aug;73(8):1330-5. Review. Japanese.

PMID:
26281686
6.

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.

Gunderson CC, Moore KN.

Future Oncol. 2015;11(5):747-57. doi: 10.2217/fon.14.313. Review.

PMID:
25757679
7.

Olaparib: a promising PARP inhibitor in ovarian cancer therapy.

Chen Y, Zhang L, Hao Q.

Arch Gynecol Obstet. 2013 Aug;288(2):367-74. doi: 10.1007/s00404-013-2856-2. Epub 2013 Apr 26. Review.

PMID:
23619942
8.

PARP inhibitors: its role in treatment of cancer.

Chen A.

Chin J Cancer. 2011 Jul;30(7):463-71. doi: 10.5732/cjc.011.10111. Review.

9.

BRCA in breast cancer: from risk assessment to therapeutic prediction.

Diamond JR, Borges VF, Eckhardt SG, Jimeno A.

Drug News Perspect. 2009 Dec;22(10):603-8. doi: 10.1358/dnp.2009.22.10.1440985. Review.

PMID:
20140280
10.

[PARP inhibitors and breast cancer: update and perspectives].

Gonçalves A.

Bull Cancer. 2012 Apr 1;99(4):441-51. doi: 10.1684/bdc.2012.1553. Review. French.

PMID:
22450359
11.

Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.

Comen EA, Robson M.

Cancer J. 2010 Jan-Feb;16(1):48-52. doi: 10.1097/PPO.0b013e3181cf01eb. Review.

12.

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.

Watkins JA, Irshad S, Grigoriadis A, Tutt AN.

Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670. Review.

13.

Olaparib, PARP1 inhibitor in ovarian cancer.

Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F, Benedetti Panici P.

Expert Opin Investig Drugs. 2012 Oct;21(10):1575-84. Epub 2012 Jul 13. Review.

PMID:
22788971
14.

The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

Sandhu SK, Yap TA, de Bono JS.

Curr Drug Targets. 2011 Dec;12(14):2034-44. Review.

PMID:
21777194
15.

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

Bouwman P, Jonkers J.

Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22. Review.

16.

Inducing synthetic lethality using PARP inhibitors.

Boss DS, Beijnen JH, Schellens JH.

Curr Clin Pharmacol. 2010 Aug;5(3):192-5. Review.

PMID:
20406170
17.

[PARP inhibitors--theoretical basis and clinical application].

Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.

Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21. Review. Polish.

18.

Predictive biomarkers for cancer therapy with PARP inhibitors.

Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G.

Oncogene. 2014 Jul 24;33(30):3894-907. doi: 10.1038/onc.2013.352. Epub 2013 Sep 16. Review.

PMID:
24037533
19.

Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Curtin NJ, Szabo C.

Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29. Review.

20.

Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.

Ratner ES, Sartorelli AC, Lin ZP.

Curr Opin Oncol. 2012 Sep;24(5):564-71. doi: 10.1097/CCO.0b013e3283564230. Review.

Items per page

Supplemental Content

Write to the Help Desk